NetApp, Inc. (NASDAQ:NTAP) last session’s volume of 3.28 million shares was higher than its average volume of 2.73 million shares. The stock, after opening at $58.67, hit $59.65 through the close by scoring 1.36%.NetApp, Inc. (NTAP) Analyst Opinion
NetApp, Inc. has a consensus outperform rating from 28 Wall Street analysts, and the number of shares currently sold short amount to at least 4.87% of shares outstanding. The stock spiked 4.26% last month and is up 7.83 this year. Wall Street is only getting more bullish on the stock, with 13 of analysts who cover NTAP having a buy-equivalent rating. Analysts have placed a $55.9 price target on NetApp, Inc., suggesting a -6.29% decline from recent close. It’s currently trading about 1.12% above its 52-week high.NetApp, Inc. Earnings Surprise
NetApp, Inc. (NTAP) surprised the stock market in its last reported earnings when it earned $0.81 a piece versus the consensus-estimated $0.69. Its revenue totaled $1.38 billion up 4.47% from the previous quarter.NetApp, Inc. (NASDAQ:NTAP) Intraday View
This stock (NTAP) is ahead of its 52-week low with 70.04%. Its last month’s stock price volatility remained 2.33% which for the week stands at 1.69%. The share price has moved forward from its 20 days moving average, trading at a distance of 4.45% and stays 12.97% away from its 50 days moving average. Over the last five days, shares have managed 7.83% gains and now is up 35.68% since hitting its 200-day moving average of $45.78. NetApp, Inc. (NTAP) has made its way to a 12-month gain of 69.32%.
Turning to AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), its shares were trading at $2.74 a retreat of $-0.07, on the trading floor. The stock, after opening at $2.8, touched a high of $2.8001 before paring much of its gains. So far, analysts are sticking with their neutral recommendations with the consensus call at 2. AVEO Pharmaceuticals, Inc. has 0 buy ratings, 0 holds and 0 sells even after the stock tumbled -35.38% from its high of $4.24 to a $329.98 million market value through last close.AVEO Pharmaceuticals, Inc. (AVEO) Consensus Price Target
The company’s consensus rating on Reuter’s scale remained unchanged from 2 to 2 during a month. Analysts set a 12-month price target of $5.67 a share. The target implies a 106.93% spike from where the shares are currently trading. Also, the current price highlights a discount of 155.47% to analysts’ high consensus price target.AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Intraday Trading
The counter witnessed a trading volume of 0.99 million shares versus an average volume of 1.99 million shares during last trading session. Its last month’s stock price volatility remained 5.23% which for the week approaches 5.16%. The lowest price the stock reached in the last trading day was $2.71 and compares with the $0.50 52-week low. The stock recovered 449.1% since its low point and has performed -1.79% year-to-date.